Irvine-based natural products company ChromaDex Corp. said today that results from a clinical study showed that its flagship product reduces high blood pressure in adults.

Shares of the company had jumped 20% earlier this week in anticipation of the news but slipped back today below the $1 mark. ChromaDex shares trade on the over-the-counter Bulletin Board.

The company earlier this year launched its first retail product line, BluScience, which contains pTeroPure, a patented antioxidant ingredient extracted from blueberries.

ChromaDex’s first human clinical study with the University of Mississippi Medical Center found that pterostilbene, a major component in pTeroPure, reduces blood pressure.

Results were presented today at the American Heart Association’s High Blood Pressure Research Conference.